Zobrazeno 1 - 10
of 248
pro vyhledávání: '"Henry J. Kaminski"'
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
ObjectivesThe objective of this research was to generate psychometric evidence supporting the myasthenia gravis (MG) symptoms patient-reported outcome (PRO) scales as a fit-for-purpose measure of severity of core symptoms of MG and provide informatio
Externí odkaz:
https://doaj.org/article/bec1fe3766134ae297bd3459e552a7f8
Autor:
James F. Howard, Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J. Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Richard J. Nowak, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D. Weiss, Małgorzata Zajda, Jos Bloemers, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W. Duda, Mark Vanderkelen, M. Isabel Leite
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Generalized myasthenia gravis (gMG) is a chronic, unpredictable disease associated with high treatment and disease burdens, with a need for more effective and well-tolerated treatments. Objectives: To evaluate the long-term safety, tolera
Externí odkaz:
https://doaj.org/article/5317ded6473646318a630c95493a4cc4
Autor:
Antoine Regnault, Thomas Morel, Christine de la Loge, Flora Mazerolle, Henry J. Kaminski, Ali A. Habib
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1573-1590 (2023)
Abstract Introduction Accurate measurement of myasthenia gravis (MG) severity is required for appropriate clinical monitoring of patients with MG and assessment of the benefit of new treatments in clinical trials. Our objective was to explore how MG
Externí odkaz:
https://doaj.org/article/131a281df393491aae95d0337bb8b940
Autor:
Quentin Lesport, Guillaume Joerger, Henry J. Kaminski, Helen Girma, Sienna McNett, Mohammad Abu-Rub, Marc Garbey
Publikováno v:
Sensors, Vol 23, Iss 18, p 7744 (2023)
Due to the precautions put in place during the COVID-19 pandemic, utilization of telemedicine has increased quickly for patient care and clinical trials. Unfortunately, teleconsultation is closer to a video conference than a medical consultation, wit
Externí odkaz:
https://doaj.org/article/87caf117c08a4cb494e9760acacdda73
Autor:
Antoine Regnault, Thomas Morel, Christine de la Loge, Flora Mazerolle, Henry J. Kaminski, Ali A. Habib
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1591-1592 (2023)
Externí odkaz:
https://doaj.org/article/eef46f92da184ba4b2e904e065f2cf8f
Autor:
Patricia Sikorski, Yaoxiang Li, Mehar Cheema, Gil I. Wolfe, Linda L. Kusner, Inmaculada Aban, Henry J. Kaminski
Publikováno v:
PLoS ONE, Vol 18, Iss 10 (2023)
Externí odkaz:
https://doaj.org/article/b2233cf645124079b978488ad84c4b8a
Autor:
Sophie Cleanthous, Ann-Christin Mork, Antoine Regnault, Stefan Cano, Henry J. Kaminski, Thomas Morel
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-14 (2021)
Abstract Background Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease, characterised by fluctuating muscle weakness which makes it challenging to assess symptom severity. Mixed methods psychometrics (MMP), which combines evidence f
Externí odkaz:
https://doaj.org/article/307ef65081e44c5291c66c41d7f2e187
Autor:
Henry J. Kaminski, Jordan Denk
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Chronic, high-dose, oral prednisone has been the mainstay of myasthenia gravis treatment for decades and has proven to be highly beneficial in many, toxic in some way to all, and not effective in a significant minority. No patient characteristics or
Externí odkaz:
https://doaj.org/article/865c252d8ea640c8882881e70721d55c
Autor:
Linda L. Kusner, Kristina Yucius, Manjistha Sengupta, Andrew G. Sprague, Dhruv Desai, Tuyen Nguyen, Klaus Charisse, Satya Kuchimanchi, Rajeev Kallanthottathil, Kevin Fitzgerald, Henry J. Kaminski, Anna Borodovsky
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 13, Iss , Pp 484-492 (2019)
Complement-mediated damage to the neuromuscular junction (NMJ) is a key mechanism of pathology in myasthenia gravis (MG), and therapeutics inhibiting complement have shown evidence of efficacy in the treatment of MG. In this study, we describe the de
Externí odkaz:
https://doaj.org/article/44b70ce344d04d39ba586958c5169aed
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Complement activation as a driver of pathology in myasthenia gravis (MG) has been appreciated for decades. The terminal complement component [membrane attack complex (MAC)] is found at the neuromuscular junctions of patients with MG. Animals with exp
Externí odkaz:
https://doaj.org/article/b4d1b5c656fc407f820fc32ec1614281